Abstract
Background: Cardiac sarcoidosis is increasingly recognized and is associated with poor prognosis. Ventricular tachycardia (VT) associated with cardiac sarcoidosis is the most likely cause of sudden death in most patients, but the mechanism has not been well established.
Hypothesis: This study investigated the mechanisms and outcome of VT associated with cardiac sarcoidosis.
Methods: The study included eight consecutive patients (five men, three women, aged 54 ± 19 years) who had sustained monomorphic VT associated with cardiac sarcoidosis in our hospital.
Results: The average ejection fraction was 43 ± 11%. Twenty‐two VTs were observed in these patients, and mean heart rate during VT was 192 ± 29 beats/min (range 144–259). The phenomenon of transient entrainment was documented in 10 of 22 (45%) VTs by ventricular pacing (eight in the active phase). Another five (23%) VTs could not be entrained, but could be initiated by programmed stimulation and terminated by rapid pacing, reproducibly. In 3 of the 22 (14%) VTs, cardioversion was required urgently because of the fast rate, while the remaining 4 (18%) could be induced during electrophysiologic study.
Conclusions: In this study, there was a high possibility that the mechanism of 15 (68%) VTs was reentry. Reentrant substrate is formed not only in association with the healing of cardiac granulomas in the inactive phase of cardiac sarcoidosis but also in the active phase. Ventricular tachycardia with cardiac sarcoidosis, even if this mechanism is reentry, has different inducibility between the active and inactive phases in an electrophysiologic study. This makes the therapy for cardiac sarcoidosis (e.g., corticosteroids, antiarrhythmic agents, and catheter ablation) difficult. The implantable cardioverter‐defibrillator is an effective treatment for ventricular tachyarrythmia with cardiac sarcoidosis.
Keywords: cardiac sarcoidosis, ventricular tachycardia, electrophysiologic test, reentry
Full Text
The Full Text of this article is available as a PDF (180.6 KB).
References
- 1. Matsui Y, Iwai K, Tachibana T, Shigematsu N, Izumi T, Homma AH, Mikami R, Hongo O, Hiraga Y, Yamamoto M: Clinicopathological study on fatal myocardial sarcoidosis. Ann NY Acad Sci 1975; 278: 455–469 [DOI] [PubMed] [Google Scholar]
- 2. Porter GH: Sarcoid heart disease. N Engl J Med 1960; 263: 1350–1357 [DOI] [PubMed] [Google Scholar]
- 3. Gozo EJ Jr, Cosnow I, Cohen HC, Okun L: The heart in sarcoidosis. Chest 1971; 60: 379–388 [DOI] [PubMed] [Google Scholar]
- 4. Fleming HA: Sarcoid heart disease. Br Heart J 1974; 36: 54–58 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Phinney AU Jr: Sarcoid of the myocardial septum with complete heart block: Report of two cases. Am Heart J 1961; 62: 270–276 [DOI] [PubMed] [Google Scholar]
- 6. Bashour FA, McConnell J, Skinner W, Hanson M: Myocardial sarcoidosis. Dis Chest 1968; 53: 413–420 [DOI] [PubMed] [Google Scholar]
- 7. Roberts WC, McAllister HA, Ferrans VJ: Sarcoidosis of the heart: A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 1977; 63: 86–105 [DOI] [PubMed] [Google Scholar]
- 8. Chinushi M, Mezaki T, Aoki Y, Nakagawa I, Washizuka T, Aizawa Y: Demonstration of transient entrainment in monomorphic sustained ventricular tachycardia associated with cardiac sarcoidosis. Jpn Circ J 2000; 64: 635–637 [DOI] [PubMed] [Google Scholar]
- 9. Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K: Steroid therapy in cardiac sarcoidosis: Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984; 85: 445–447 [DOI] [PubMed] [Google Scholar]
- 10. Shammas RL, Movahed A: Sarcoidosis of the heart. Clin Cardiol 1993; 16: 462–472 [DOI] [PubMed] [Google Scholar]
- 11. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M: Cardiac sarcoidosis: Diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996; 10: 495–510 [DOI] [PubMed] [Google Scholar]
- 12. James TN: Sarcoid heart disease: Clinicopathologic correlations. Circulation 1977; 56: 320–326 [DOI] [PubMed] [Google Scholar]
- 13. Disease Control Division, Health Service Bureau, Ministry of Health and Welfare. A manual of diagnosis and therapy for the intractable diseases for general practitioner, p. 77 (in Japanese). Tokyo: Roppoh, 1990. [Google Scholar]
- 14. Palevsky HI, Alavi A: Gallium‐67‐citrate scanning in the assessment of disease activity in sarcoidosis. J Nucl Med 1992; 33: 751–755 [PubMed] [Google Scholar]
- 15. Aizawa Y, Niwano S, Chinushi M, Tamura M, Kusano Y, Miyajima T, Kitazawa H, Shibata A: Incidence and mechanism of interruption of reentrant ventricular tachycardia with rapid pacing. Circulation 1992; 85: 589–595 [DOI] [PubMed] [Google Scholar]
- 16. Waldo AL, Henthorn RW, Plumb VJ, MacLean WA: Demonstration of the mechanism of transient entrainment and interruption of ventricular tachycardia with rapid atrial pacing. J Am Coll Cardiol 1984; 3: 422–430 [DOI] [PubMed] [Google Scholar]
- 17. Okumura K, Olshansky B, Henthorn RW, Epstein AE, Plumb VJ, Waldo AL: Demonstration of the presence of slow conduction during sustained ventricular tachycardia in man: Use of entrainment of the tachycardia. Circulation 1987; 75: 369–378 [DOI] [PubMed] [Google Scholar]
- 18. Chinushi M, Aizawa Y, Kusano Y, Washizuka T, Miyajima T, Naitho N, Takahashi K, Shibata A: Radiofrequency current catheter ablation for ventricular tachycardia. Jpn Circ J 1994; 58: 315–325 [DOI] [PubMed] [Google Scholar]
- 19. Morady F, Kadish A, Rosenheck S, Calkins H, Kou WH, deBuitler M, Sousa J: Concealed entrainment as a guide for catheter ablation of ventricular tachycardia in patients with prior myocardial infarction. J Am Coll Car‐diol 1991; 49: 207–220 [DOI] [PubMed] [Google Scholar]
- 20. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Natterson PD, Wiener I: Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993; 88 (part 1): 1647–1670 [DOI] [PubMed] [Google Scholar]
- 21. Fleming HA: Sarcoid heart disease: A review and an appeal. Thorax 1980; 35: 641–643 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Paz HL, McCormick DJ, Kutalek SP, Patchefsky A: The automated implantable cardiac defibrillator. Chest 1994; 106: 1603–1607 [DOI] [PubMed] [Google Scholar]
- 23. Mezaki T, Chinushi M, Washizuka T, Furushima H, Chinushi Y, Ebe Katuya, Okumura H, Aizawa Y: Discrepancy between inducibility of ventricular tachycardia and activity of cardiac sarcoidosis—requirement of defibrillator implantation for the inactive stage of cardiac sarcoidosis. Intern Med 2001; 40: 731–735 [DOI] [PubMed] [Google Scholar]
- 24. Lorell B, Alderman EL, Mason JW: Cardiac sarcoidosis: Diagnosis with endomyocardial biopsy and treatment with corticosteroids. Am J Cardiol 1978; 42: 143–146 [DOI] [PubMed] [Google Scholar]
- 25. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882–1890 [DOI] [PubMed] [Google Scholar]
- 26. Stein E, Stimmel B, Siltzbach LE: Clinical course of cardiac sarcoidosis. Ann NY Acad Sci 1976; 278: 470–474 [DOI] [PubMed] [Google Scholar]
- 27. Tornling G, Olsson G, von Unge H: Ventricular fibrillation in myocardial sarcoidosis. Eur J Respir Dis 1985; 66: 347–349 [PubMed] [Google Scholar]